Transport of Extracellular Vesicles across the Blood-Brain Barrier: Brain Pharmacokinetics and Effects of Inflammation
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
Extracellular vesicles can cross the blood–brain barrier (BBB), but little is known about passage. Here, we used multiple-time regression analysis to examine the ability of 10 exosome populations derived from mouse, human, cancerous, and non-cancerous cell lines to cross the BBB. All crossed the BBB, but rates varied over 10-fold. Lipopolysaccharide (LPS), an activator of the innate immune system, enhanced uptake independently of BBB disruption for six exosomes and decreased uptake for one. Wheatgerm agglutinin (WGA) modulated transport of five exosome populations, suggesting passage by adsorptive transcytosis. Mannose 6-phosphate inhibited uptake of J774A.1, demonstrating that its BBB transporter is the mannose 6-phosphate receptor. Uptake rates, patterns, and effects of LPS or WGA were not predicted by exosome source (mouse vs. human) or cancer status of the cell lines. The cell surface proteins CD46, AVβ6, AVβ3, and ICAM-1 were variably expressed but not predictive of transport rate nor responses to LPS or WGA. A brain-to-blood efflux mechanism variably affected CNS retention and explains how CNS-derived exosomes enter blood. In summary, all exosomes tested here readily crossed the BBB, but at varying rates and by a variety of vesicular-mediated mechanisms involving specific transporters, adsorptive transcytosis, and a brain-to-blood efflux system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 On-bead flow cytometry of exosome populations isolated from supernatants of 4 different cell lines, captured on streptavidin beads coated with biotinylated anti-CD63 mAbs and stained with the labeled detection Abs specific for CD46, αVβ6, αVβ3 and ICAM1 as described in Methods. Data are relative fluorescence intensity (RFI) values calculated as mean fluorescence intensity (MFI) of an experimental sample/MFI of an isotype control Ab. [White peaks = experimental samples; hatched peaks = isotope controls]. Note that exosomes produced by non-malignant cells (HaCaT and primary T cells) appear to differ from exosomes produced by malignant cells by the absence of αVβ3 and lower expression levels of αVβ6. Representative results are from 1 to 3 detection experiments performed with each exosome population.](https://figures.cochat.ai/paper-figures/624d7ee716904379955ce30fbf39b5dc/transport-of-extracellular-vesicles-across-the-blood-brain-barrier-brain-figure-2.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, EVs have inherent targeting capabilities and can cross the BBB, facilitating efficient delivery of therapeutic cargo to the CNS [54–57].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Brain-derived EVs have been found to harbor the ability to penetrate the BBB. This breakdown is crucial as it potentially allows for releasing these EVs into peripheral circulation [54–57].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“sEVs can cross the blood–brain barrier and deliver cargo with crucial roles in many neurological disorders [17–23].”
From Differential RNA packaging into small extracellular vesicles by neurons and astrocytes (2021) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099 · cited 3×
“EVs we refer to as “exosomes” were isolated by mini-size exclusion chromatography (SEC) from supernatants of 10 different human or murine cell lines (Table 1) and characterized according to the Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018) criteria [2], as is routinely done in our laborato…”
BackgroundMethodShedding light on the cell biology of extracellular vesicles
van Niel, G., D'Angelo, G., & Raposo, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.125 · Cited by 8,369 · cited 2×
“of parent cells, where they are formed by inverse membrane invagination as intraluminal vesicles inside multivesicular bodies (MVBs) [4].”
BackgroundExtracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099 · cited 1×
“Exosomes are a subset of small extracellular vesicles (EVs) that are produced by all normal and malignant cells and are present in all body fluids [1].”
BackgroundGraphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
Exosomes as drug delivery vehicles for Parkinson’s disease therapy
Haney, M. J., Klyachko, N. L., Zhao, Y., Gupta, R., Plotnikova, E. G., He, Z., Patel, T., Piroyan, A., Sokolsky, M., Kabanov, A. V., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.033 · Cited by 2,009 · cited 1×
“, drug-loaded exosomes enter the brain using the same mechanisms as those employed by the parent cells [12].”
BackgroundAbels, E. R., & Breakefield, X. O. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0366-z · Cited by 1,678 · cited 1×
“Among the various EVs, exosomes are sized at 30–150 nm in diameter and are of special interest because of their origin, their ability to freely circulate and infiltrate various tissues and their molecular content mirroring that of parental cells [3].”
BackgroundZhang, H., Freitas, D., Kim, H. S., Fabijanic, K., Li, Z., Chen, H., Mark, M. T., Molina, H., Martin, A. B., Bojmar, L., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0040-4 · Cited by 1,613 · cited 1×
“The orientation of surface proteins in exosome membranes resembles that in the cell membrane of parent cells [5].”
BackgroundExtracellular Vesicles: Unique Intercellular Delivery Vehicles
Maas, S. L. N., Breakefield, X. O., & Weaver, A. M. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.11.003 · Cited by 1,429 · cited 2×
“Exosomes serve as an intercellular communication system, shuttling messages between cells and also conveying peptides, proteins, and genetic materials from parental to recipient cells [6].”
BackgroundFrom blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery
Banks, W. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.21 · Cited by 1,204
Self-citationPlasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676
Self-citation
Research works printed but not linked: 1
- Nicolini, M., and Zatta, P.F. (1994). Glycoconjugates and anionic sites in the blood-brain barrier. Glycobiology and the Brain, Pergamon Press.
Cited by
The Machinery of Exosomes: Biogenesis, Release, and Uptake
Krylova, S. V., & Feng, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021337 · Cited by 678
“Adsorptive transcytosis, a mechanism that facilitates transport through the cell by interactions of positive and negative molecular charges, has also been suggested [106].”
BackgroundExtracellular vesicles through the blood–brain barrier: a review
Ramos-Zaldívar, H. M., Polakovicova, I., Salas-Huenuleo, E., Corvalán, A. H., Kogan, M. J., Yefi, C. P., & Andia, M. E. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-022-00359-3 · Cited by 287
“LPS increased uptake of six human EVs populations and decreased uptake from one murine type [52].”
BackgroundMethodInfluentialUnlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery
Elliott, R. O., & He, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010122 · Cited by 260
“into brain microvascular endothelial cells (BMECs) [42,43] with migration through BMECs found primarily to be through the transcellular route rather than tight junctions involved in the paracellular pathway [42].”
BackgroundExosomes based strategies for brain drug delivery
Rehman, F. U., Liu, Y., Zheng, M., & Shi, B. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2022.121949 · Cited by 229
Development of Extracellular Vesicle Therapeutics: Challenges, Considerations, and Opportunities
Claridge, B., Lozano, J., Poh, Q. H., & Greening, D. W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.734720 · Cited by 227
Harnessing extracellular vesicle heterogeneity for diagnostic and therapeutic applications
Carney, R. P., Mizenko, R. R., Bozkurt, B. T., Lowe, N., Henson, T., Arizzi, A., Wang, A., Tan, C., & George, S. C. (2025) · Nature Nanotechnology · doi:10.1038/s41565-024-01774-3 · Cited by 208
“…EV therapeutics are (1) high cellular uptake 78,79 , (2) cell/tissue tropism 6 , (3) immunomodulation 78,80 , (4) endothelial barrier crossing 21,81 , (5) protective effects (for example, neuroprotection) 82,83 , (6) regenerative properties (for example, angiogenesis) 84–87 and (7) cell…”
Exosome-Based Smart Drug Delivery Tool for Cancer Theranostics
Kar, R., Dhar, R., Mukherjee, S., Nag, S., Gorai, S., Mukerjee, N., Mukherjee, D., Vatsa, R., Chandrakanth Jadhav, M., Ghosh, A., et al. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c01329 · Cited by 210
Mesenchymal stem cell secretome for regenerative medicine: Where do we stand?
Trigo, C. M., Rodrigues, J. S., Camões, S. P., Solá, S., & Miranda, J. P. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.004 · Cited by 252
Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier
Li, J., Zheng, M., Shimoni, O., Banks, W. A., Bush, A. I., Gamble, J. R., & Shi, B. (2021) · Advanced Science · doi:10.1002/advs.202101090 · Cited by 202
Self-citationA critical systematic review of extracellular vesicle clinical trials
Mizenko, R. R., Feaver, M., Bozkurt, B. T., Lowe, N., Nguyen, B., Huang, K., Wang, A., & Carney, R. P. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12510 · Cited by 185
Lipid nanoparticle-mediated drug delivery to the brain
Khare, P., Edgecomb, S. X., Hamadani, C. M., Tanner, E. E. L., & S Manickam, D. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114861 · Cited by 187
Insight into Extracellular Vesicle-Cell Communication: From Cell Recognition to Intracellular Fate
Ginini, L., Billan, S., Fridman, E., & Gil, Z. (2022) · Cells · doi:10.3390/cells11091375 · Cited by 176
“Tested in a recent study, exosomes of different origins—variably expressed CD46, AVβ6, AVβ3, and ICAM-1—readily crossed the BBB, suggesting that this might be regulated in part by differences in integrin expression levels on exosomal surfaces [99].”
BackgroundGarlic exosome-like nanoparticles reverse high-fat diet induced obesity via the gut/brain axis
Sundaram, K., Mu, J., Kumar, A., Behera, J., Lei, C., Sriwastva, M. K., Xu, F., Dryden, G. W., Zhang, L., Chen, S., et al. (2022) · Theranostics · doi:10.7150/thno.65427 · Cited by 176
“Circulating nanoparticles such as exosomes can cross the BBB in both directions [24, 25].”
BackgroundZhu, Z., Zhai, Y., Hao, Y., Wang, Q., Han, F., Zheng, W., Hong, J., Cui, L., Jin, W., Ma, S., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12255 · Cited by 175
Abdelsalam, M., Ahmed, M., Osaid, Z., Hamoudi, R., & Harati, R. (2023) · Pharmaceuticals · doi:10.3390/ph16040571 · Cited by 174
“This is because inflammation disrupts the BBB and enhances vesicular penetration, where exosomes are absorbed by brain microvascular endothelial cells through endocytosis [29].”
BackgroundInfluentialPalanisamy, C. P., Pei, J., Alugoju, P., Anthikapalli, N. V. A., Jayaraman, S., Veeraraghavan, V. P., Gopathy, S., Roy, J. R., Janaki, C. S., Thalamati, D., et al. (2023) · Theranostics · doi:10.7150/thno.83066 · Cited by 165
“Furthermore, macrophage/microglial clearance shortens the circulation time of EVs [223].”
BackgroundLiang, Y., Iqbal, Z., Lu, J., Wang, J., Zhang, H., Chen, X., Duan, L., & Xia, J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2022.10.008 · Cited by 162
“29 Thus, deciphering the mechanism of this highly selective barrier will further facilitate the development of new approaches to aid the crossing of the BBB by rationally designing effective exo-some-based brain delivery systems.”
Towards artificial intelligence-enabled extracellular vesicle precision drug delivery
Greenberg, Z., Graim, K. S., & He, M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114974 · Cited by 174
Kooijmans, S. A. A., de Jong, O. G., & Schiffelers, R. M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.017 · Cited by 139
Tao, B., Du, R., Zhang, X., Jia, B., Gao, Y., Zhao, Y., & Liu, Y. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.10.007 · Cited by 149
Entry and exit of extracellular vesicles to and from the blood circulation
Iannotta, D., Amruta, A., Kijas, A. W., Rowan, A. E., & Wolfram, J. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01522-z · Cited by 158
“Adsorptive-mediated transcytosis is another mechanism proposed for the blood–brain barrier crossing of EVs 57,58 .”
Inflammation‐driven brain and gut barrier dysfunction in stress and mood disorders
Doney, E., Cadoret, A., Dion‐Albert, L., Lebel, M., & Ménard, C. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15239 · Cited by 150
“These vesicles can cross the BBB and stimulate trafficking of immune cells into the CNS (Banks et al., 2020).”
BackgroundInfluentialDrug Delivery Systems in Regenerative Medicine: An Updated Review
Mansour, A., Romani, M., Acharya, A. B., Rahman, B., Verron, É., & Badran, Z. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020695 · Cited by 145
“, blood-brain barrier), and capability to transmit biological signals between cells [128], EVs have been considered in the context of regenerative medicine and delivery systems [129,130].”
BackgroundExosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies
Mehdizadeh, S., Mamaghani, M., Hassanikia, S., Pilehvar‐Soltanahmadi, Y., & Ertaş, Y. N. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03352-8 · Cited by 150
“Studies suggest that exosome surface engineering with LDLR-binding ligands can further enhance BBB penetration, offering alternative pathways for brain-targeted therapies [64].”
Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets
Taghdiri, M., & Mussolino, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137333 · Cited by 145
“By carefully selecting the origin of the EV-producing cells, the resulting vesicles can be immunologically inert with a beneficial gain in cytotoxicity and can be naturally competent to cross natural biological barriers such as the blood-brain barrier to deliver their cargo to neurons [102].”
BackgroundResveratrol-loaded macrophage exosomes alleviate multiple sclerosis through targeting microglia
Zheng, X., Sun, K., Liu, Y., Yin, X., Zhu, H., Yu, F., & Zhao, W. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.026 · Cited by 116
Extracellular Vesicles in neural cell interaction and CNS homeostasis
Schnatz, A., Müller, C., Brahmer, A., & Krämer‐Albers, E. (2021) · FASEB BioAdvances · doi:10.1096/fba.2021-00035 · Cited by 119
Xu, F., Mu, J., Teng, Y., Zhang, X., Sundaram, K., Sriwastva, M. K., Kumar, A., Lei, C., Zhang, L., Liu, Q. M., et al. (2021) · Small · doi:10.1002/smll.202105385 · Cited by 117
Sanadgol, N., Abedi, M., Hashemzaei, M., Kamran, Z., Khalseh, R., Beyer, C., & Voelz, C. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03528-2 · Cited by 123
“Current research is exploring the bioengineering of EVs for stroke therapy, their interactions with the BBB, and the challenges and prospects of EV-based therapies for brain disorders [5, 18].”
Engineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain
Wu, J. R., Hernandez, Y., Miyasaki, K. F., & Kwon, E. J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114820 · Cited by 97
Joshi, B. S., & Zuhorn, I. S. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14974 · Cited by 99
“Recently, adsorptive transcytosis was shown to play a role in exosome transport across the BBB (Banks et al., 2020), suggesting an involvement of electrostatic interaction between exosome membrane components and endothelial cell surface receptors (Villegas & Broadwell, 1993; Banks et al.”
BackgroundInfluentialKuo, M., Liu, S. C.-H., Hsu, Y.-F., & Wu, R. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00775-x · Cited by 107
“Given that circRNAs are brain-enriched [162] and predominantly located at synapses and dendrites [226], an age-dependent accumulation of circRNAs in the CNS has been discovered in model organisms such as flies, worms, and mice [37, 203].”
BackgroundInfluentialExosome-Based Carrier for RNA Delivery: Progress and Challenges
Lu, Y., Huang, W., Li, M., & Zheng, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020598 · Cited by 93
“(3) Exosomes can cross the blood-brain barrier (BBB) by a variety of mechanisms [25,26].”
BackgroundEngineered EVs designed to target diseases of the CNS
Nieland, L., Mahjoum, S., Grandell, E., Breyne, K., & Breakefield, X. O. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.009 · Cited by 100
Eitan, E., Thornton‐Wells, T. A., Elgart, K., Erden, E., Gershun, E., Levine, A. A., Volpert, O. V., Azadeh, M., Smith, D. G., & Kapogiannis, D. (2023) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2023.13 · Cited by 101
Therapeutic Application of Exosomes in Inflammatory Diseases
Suh, J. H., Joo, H. S., Hong, E. B., Lee, H. J., & Lee, J. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031144 · Cited by 94
“They can pass through the blood–brain barrier, providing a means to deliver drugs to the brain [57].”
BackgroundSex differences in the blood–brain barrier: Implications for mental health
Dion‐Albert, L., Binder, L. B., Daigle, B., Hong-Minh, A., Lebel, M., & Ménard, C. (2022) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2022.100989 · Cited by 107
“Moreover, current literature suggests that crossing of biological barriers may be a common feature amongst exosomes, and exosomes could cross the BBB using a variety of mechanisms reflecting their cellular origin (Banks et al., 2020).”
BackgroundTolomeo, A. M., Zuccolotto, G., Malvicini, R., Lazzari, G. D., Penna, A., Franco, C., Caicci, F., Magarotto, F., Quarta, S., Pozzobon, M., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020548 · Cited by 98
“, blood–brain barrier, BBB) reaching distant sites [3,4].”
Osaid, Z., Haider, M. A., Hamoudi, R., & Harati, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115635 · Cited by 94
Targeted nonviral delivery of genome editors in vivo
Tsuchida, C. A., Wasko, K. M., Hamilton, J. R., & Doudna, J. A. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307796121 · Cited by 90
Extracellular vesicles for the treatment of central nervous system diseases
Gratpain, V., Mwema, A., Labrak, Y., Muccioli, G. G., Pesch, V. V., & Rieux, A. D. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.006 · Cited by 82
Biodistribution of therapeutic extracellular vesicles
Gupta, D., Wiklander, O. P. B., Wood, M. J. A., & Andaloussi, S. E. (2023) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2023.12 · Cited by 92
Gu, W., Luozhong, S., Cai, S., Londhe, K., Elkasri, N., Hawkins, R. D., Yuan, Z., Greene, K. S., Yin, Y., Cruz, M., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01150-x · Cited by 93
“Such alterations facilitate the selective accumulation of leucocyte-derived EVs within neuro-inflammatory regions 6–10 , Establishing robust delivery capabilities across the BBB even under conditions of mild inflammation remains of paramount importance.”
Milk Exosomes: Next-Generation Agents for Delivery of Anticancer Drugs and Therapeutic Nucleic Acids
Timofeeva, A. M., Paramonik, A. P., Sedykh, S. E., & Nevinsky, G. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210194 · Cited by 83
Liquid biopsies to occult brain metastasis
Rehman, A. U., Κhan, P., Maurya, S. K., Siddiqui, J. A., Santamaria‐Barria, J. A., Batra, S. K., & Nasser, M. W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01577-x · Cited by 78
“EVs are critically involved at this junction, with their repertoires modulating the changes after the interaction with the tumor cells and EVs, which can breach the physiological barriers [126, 178, 183, 184].”
BackgroundDave, K. M., Pinky, P. P., & Manickam, D. S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114068 · Cited by 84
The role of Extracellular Vesicles during CNS development
Sangani, N. B., Gomes, A. R., Curfs, L., & Reutelingsperger, C. P. M. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102124 · Cited by 73
“showed that exosomes from different cell lines were able to pass the BBB, albeit at different rates and engaging different molecular transport mechanisms (Banks et al., 2020).”
BackgroundThe Yin and Yang of Microglia-Derived Extracellular Vesicles in CNS Injury and Diseases
Ghosh, M., & Pearse, D. D. (2024) · Cells · doi:10.3390/cells13221834 · Cited by 77
Extracellular vesicles for improved tumor accumulation and penetration
Bie, N., Yong, T., Wei, Z., Gan, L., & Yang, X. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114450 · Cited by 68
Delivery of mitochondria via extracellular vesicles – A new horizon in drug delivery
Manickam, D. S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.045 · Cited by 61
Exosomes for Regulation of Immune Responses and Immunotherapy
Hussain, M. W. A., Jahangir, S. R. T., Ghosh, B., Yesmin, F., Anis, A., Satil, S. N., Anwar, F., & Rashid, M. H. (2022) · Journal of Nanotheranostics · doi:10.3390/jnt3010005 · Cited by 68
Khalil, A., Barras, A., Boukherroub, R., Tseng, C., Devos, D., Burnouf, T., Neuhaus, W., & Szunerits, S. (2023) · Nanoscale Horizons · doi:10.1039/d3nh00306j · Cited by 64
Mauer, J., Xavier, G., Ota, V., Chehimi, S. N., Mafra, F., Cuóco, C., Ito, L. T., Ormond, R., Asprino, P. F., Oliveira, A., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02326-4 · Cited by 66
“They have become targets of interest in research of neurological and psychiatric disorders because they are small enough to cross the blood-brain barrier [14].”
BackgroundFilannino, F. M., Panaro, M. A., Benameur, T., Pizzolorusso, I., & Porro, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031629 · Cited by 60
“EVs are able to pass the BBB to enter the brain from the periphery or to exit via the circulating [54] CSF or the lymphatic system; due to this, they may be studied as potential biomarkers or therapeutic carriers of CNS diseases [55].”
BackgroundJahromi, L. P., Rothammer, M., & Fuhrmann, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115028 · Cited by 63
CAR-T cell-derived exosomes: a new perspective for cancer therapy
Sani, F., Shojaei, S., Tabatabaei, S. A., Khorraminejad‐Shirazi, M., Latifi, M., Sani, M., & Azarpira, N. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03783-4 · Cited by 68
“Exosomes can even pass through the blood-brain barrier, which separates the blood from the brain [19].”
BackgroundMicrobubbles versus Extracellular Vesicles as Therapeutic Cargo for Targeting Drug Delivery
Ullah, M., Kodam, S. P., Mu, Q. S., & Akbar, A. (2021) · ACS Nano · doi:10.1021/acsnano.0c10689 · Cited by 62
The role of exosomes in intercellular and inter‐organ communication of the peripheral nervous system
Bischoff, J., Schulz, A., & Morrison, H. (2022) · FEBS Letters · doi:10.1002/1873-3468.14274 · Cited by 65
Charge‐Reversed Exosomes for Targeted Gene Delivery to Cartilage for Osteoarthritis Treatment
Zhang, C., Pathrikar, T. V., Baby, H. M., Li, J., Zhang, H., Selvadoss, A., Ovchinnikova, A., Ionescu, A. M., Chubinskaya, S., Miller, R. E., et al. (2024) · Small Methods · doi:10.1002/smtd.202301443 · Cited by 68
Dave, K. M., Venna, V. R., Rao, K., Stolz, D. B., Brady, B. T., Quaicoe, V. A., Maniskas, M. E., Hildebrand, E. E., Green, D., Chen, M., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.065 · Cited by 61
Nanomedicine at the crossroads – A quick guide for IVIVC
Mast, M.-P., Modh, H., Champanhac, C., Wang, J., Storm, G., Krämer, J., Mailänder, V., Pastorin, G., & Wacker, M. G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113829 · Cited by 59
Anastasi, F., Masciandaro, S. M., Carratore, R. D., Dell’Anno, M. T., Signore, G., Falleni, A., McDonnell, L. A., & Bongioanni, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062951 · Cited by 56
“Moreover, sEV can cross the blood–brain barrier and therefore represent an easily accessible source of central nervous system (CNS) biomarkers [14].”
BackgroundSzwedowicz, U., Łapińska, Z., Gajewska-Naryniecka, A., & Choromańska, A. (2022) · Molecules · doi:10.3390/molecules27041303 · Cited by 66
Tissue Engineering and Regenerative Medicine: Perspectives and Challenges
Hoang, V. T., Nguyen, Q. T., Phan, T. T. K., Pham, T. H., Dinh, N. T. H., Anh, L. P. H., Dao, L. T. M., Bui, V. D., Dao, H., Le, D. S., et al. (2025) · MedComm · doi:10.1002/mco2.70192 · Cited by 77
Yerneni, S. S., Solomon, T. J., Smith, J. D., & Campbell, P. G. (2021) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2021.130069 · Cited by 60
Zhou, F., Ebea, P. O., Mutai, E., Wang, H., Sukreet, S., Navazesh, S. E., Dogan, H., Li, W., Cui, J., Ji, P., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.838543 · Cited by 79
“Exosomes travel to adjacent and distant recipient cells and play an important role in cell-to-cell communication (1), including transfer across the blood-brain barrier (BBB) (2, 3).”
BackgroundInfluentialExtracellular vesicles: New horizons in neurodegeneration
Chen, J., Tian, C., Xiong, X., Yang, Y., & Zhang, J. (2025) · eBioMedicine · doi:10.1016/j.ebiom.2025.105605 · Cited by 53
Extracellular Vesicles and the Stress System
Makrygianni, E. A., & Chrousos, G. P. (2022) · Neuroendocrinology · doi:10.1159/000527182 · Cited by 61
Bone Cell Exosomes and Emerging Strategies in Bone Engineering
Vig, S., & Fernandes, M. H. (2022) · Biomedicines · doi:10.3390/biomedicines10040767 · Cited by 81
Extracellular vesicles: translational research and applications in neurology
Manolopoulos, A., Yao, P. J., & Kapogiannis, D. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01080-z · Cited by 63
“Owing to their ability to cross the blood–brain barrier 11 (BBB), their presence in accessible biofluids, including blood 12 , cerebrospinal fluid 13 (CSF) and, potentially, saliva 14 and urine 15 , and their highly variable cargoes, brain-derived EVs (BDEVs) provide a powerful platform for the…”
Mesenchymal stem cell therapy for neurological disorders: The light or the dark side of the force?
Isaković, J., Šerer, K., Barišić, B., & Mitrečić, D. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1139359 · Cited by 65
“These exosomes can cross the BBB and exert neuroprotective effects (D’angelo et al., 2020).”
BackgroundInfluentialStem Cell Therapies for Progressive Multiple Sclerosis
Smith, J. A., Nicaise, A. M., Ionescu, R.-B., Hamel, R., Peruzzotti‐Jametti, L., & Pluchino, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.696434 · Cited by 56
“A recent combined systematic approach has reviewed existing evidence of human safety, BBB penetrance, demonstrable efficacy, and mechanistic targeting of licensed drugs for repurposing in PMS (Cunniffe et al., 2021).”
BackgroundInfluentialLundy, D. J., Nguyen, H. H., & Hsieh, P. C. H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081193 · Cited by 52
Majeau, N., Archambault, A. F., Gérard, C., Rousseau, J., Yaméogo, P., & Tremblay, J. P. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.023 · Cited by 55
The multiple faces of extracellular vesicles released by microglia: Where are we 10 years after?
Gabrielli, M., Raffaele, S., Fumagalli, M., & Verderio, C. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.984690 · Cited by 60
“Further lipidomic and transcriptomic data in the years to come will increase our understanding of microglial EVs signaling to the microenvironment and might help the design of engineered vesicles for targeted delivery of biomolecules across the CNS barriers (Banks et al., 2020), accelerating the use of EVs as therapeu…”
BackgroundNative and engineered exosomes for inflammatory disease
Ma, X., Liu, B., Fan, L., Liu, Y., Zhao, Y., Ren, T., Li, Y., & Li, Y. (2022) · Nano Research · doi:10.1007/s12274-022-5275-5 · Cited by 57
“Furthermore, as a cell-free therapy, exosomes can avoid the inflammatory response caused by unnecessary immunogenicity and are safer than traditional cell therapy [20].”
BackgroundBarnett, M. M., Reay, W. R., Geaghan, M. P., Kiltschewskij, D. J., Green, M. J., Weidenhofer, J., Glatt, S. J., & Cairns, M. J. (2023) · Science Advances · doi:10.1126/sciadv.adi4386 · Cited by 55
“( 89 ).”
Extracellular Vesicles for the Diagnosis of Parkinson's Disease: Systematic Review and Meta‐Analysis
Xylaki, M., Chopra, A., Weber, S., Bartl, M., Outeiro, T. F., & Mollenhauer, B. (2023) · Movement Disorders · doi:10.1002/mds.29497 · Cited by 55
“EVs can cross the blood–brain barrier (BBB) in both directions and can, therefore, act as mediators between the CNS and the periphery.(34,35) These properties render EVs a very attractive biomarker; they can carry the contents of specific cell types from different organs in biological fluids that are easily collected…”
BackgroundMalaguarnera, M., & Cabrera‐Pastor, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810068 · Cited by 53
“Given that EVs released by cells can cross the blood–brain barrier (BBB) [16], their isolation from peripheral blood facilitates detection and analysis using techniques such as chromatography size exclusion, Western blotting, enzyme-linked immunosorbent assay, flow cytometry, quantitative real-time…”
BackgroundMethodEmerging role of exosomes and exosomal microRNA in cancer: pathophysiology and clinical potential
Elewaily, M. I., & Elsergany, A. R. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03534-5 · Cited by 54
“Because of its ability to cross BBB or to 1 3 cause its destruction, exosomes can mediate CNS invasion.”
BackgroundInfluentialExtracellular vesicles (exosomes and ectosomes) play key roles in the pathology of brain diseases
Meldolesi, J. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00040-5 · Cited by 47
Targeted Drug Delivery to the Central Nervous System Using Extracellular Vesicles
Zhou, L., Kodidela, S., Godse, S., Thomas-Gooch, S. M., Kumar, A., Raji, B., Zhi, K., Kochat, H., & Kumar, S. (2022) · Pharmaceuticals · doi:10.3390/ph15030358 · Cited by 54
“The mechanism by which EVs traverse the BBB is still unclear [37].”
BackgroundD’souza, A. A., Nozohouri, S., Bleier, B. S., & Amiji, M. M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03433-5 · Cited by 52
“Recently, it has been shown that exosomes display a high targeting affinity for neurons upon intravenous administration, and they are reported to cross the intact BBB [129].”
BackgroundWang, C.-C., Hu, X., Long, Y.-F., Huang, H.-R., He, Y., Xu, Z., & Qi, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123014 · Cited by 54
Jakl, V., Ehmele, M., Winkelmann, M., Ehrenberg, S., Eiseler, T., Friemert, B., Rojewski, M., & Schrezenmeier, H. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1107055 · Cited by 52
“, blood–brain barrier) (Banks et al., 2020), ease of sterilization (e.”
Zhao, M., Li, Q., Chai, Y., Rong, R., He, L., Zhang, Y., Cui, H., Xu, H. P., Zhang, X., Wang, Z., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03238-9 · Cited by 51
“This targeted delivery is hypothesized to reduce the clearance rate of these vesicles relative to unmodified Exo, thereby substantially increasing the MTX concentration within the CSF. Research has indicated that all exosomes could cross the BBB with different traversal rates [56].”
Targeting of Extracellular Vesicle-Based Therapeutics to the Brain
Williams, A., Branscome, H., Kashanchi, F., & Batrakova, E. V. (2025) · Cells · doi:10.3390/cells14070548 · Cited by 51
Extracellular Vesicles at CNS barriers: Mode of action
Krämer‐Albers, E. (2022) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2022.102569 · Cited by 52
Exosomes as drug delivery systems in glioma immunotherapy
Hao, X., Wang, S., Wang, L., Li, J., Li, Y., & Liu, J. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02611-4 · Cited by 50
Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles
Ludwig, N., Rao, A., Sandlesh, P., Yerneni, S. S., Swain, A. D., Bullock, K. M., Hansen, K. M., Zhang, X., Jaman, E., Allen, J., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab153 · Cited by 53
Self-citationExosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges
Cano, A. C., Muñoz-Morales, Á., Sánchez‐López, E., Ettcheto, M., Souto, E. B., Camins, A., Boada, M., & Ruiz, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010298 · Cited by 52
“Because of these, crossing the BBB has gained much attention within the scientific and health communities.”
BackgroundInfluentialExosomes as nature's nano carriers: Promising drug delivery tools and targeted therapy for glioma
Rana, R., Devi, S. N., Bhardwaj, A. K., Yashavarddhan, M. H., Bohra, D., & Ganguly, N. K. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117754 · Cited by 51
Schwann Cell-Derived Exosomal Vesicles: A Promising Therapy for the Injured Spinal Cord
Ghosh, M., & Pearse, D. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417317 · Cited by 51
“…can efficiently traverse the blood–brain or the blood–spinal cord barrier (BBB, BSCB) due to their small size and lipid bilayer composition [93]; (3) recipient cell targeting by receptor systems or plasma membrane fusion [103,104], which allows for more precise and effective delivery to…”
BackgroundMethodTargeting Capabilities of Native and Bioengineered Extracellular Vesicles for Drug Delivery
Frolova, L., & Li, I. T. S. (2022) · Bioengineering · doi:10.3390/bioengineering9100496 · Cited by 49
“The mechanism behind this is poorly understood, but exosomes are hypothesized to be transported to the brain via vesicular transport, known as transcytosis [1].”
BackgroundBasic Guide for Approaching Drug Delivery with Extracellular Vesicles
Brezgin, S. A., Danilik, O., Yudaeva, A., Kachanov, A., Kostyusheva, A. P., Karandashov, I. V., Ponomareva, N., Zamyatnin, A. A., Parodi, A., Chulanov, V., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910401 · Cited by 51
“Furthermore, EVs can cross many biological barriers (e.g., blood–brain barrier [4]) and deliver nucleic acids, proteins, small-molecule compounds, and other cargo [5].”
BackgroundQuan, J., Liu, Q., Li, P., Yang, Z., Zhang, Y., Zhao, F., & Zhu, G. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04160-5 · Cited by 50
“Although Exo can be uniformly taken up by the brain, the uptake mechanisms of Exo from different sources are diverse and often nonlinear, possibly related to brain-to-blood efflux [94].”
Extracellular vesicle-mediated bidirectional communication between heart and other organs
Gabisonia, K., Khan, M., & Recchia, F. A. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00659.2021 · Cited by 46
Stone, T. W., & Williams, R. O. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16015 · Cited by 49
“Large molecules, including proteins, are usually excluded, but may bind to endothelial surfaces to be taken into cells by endocytosis or pinocytosis, and transported intracellularly for later secretion within extracellular vesicles including exosomes (Banks et al., 2020 ).”
Extracellular Vesicles in Amyotrophic Lateral Sclerosis
McCluskey, G., Morrison, K. E., Donaghy, C. G., René, F., Duddy, W. J., & Duguez, S. (2022) · Life · doi:10.3390/life13010121 · Cited by 43
“They are able to cross the blood–brain barrier and therefore are a means of intercellular signalling to and from the central nervous system (CNS) [47].”
BackgroundInfluentialCosta, M. H., Costa, M. S., Painho, B., Sousa, C. D., Carrondo, I., Oltra, E., Pelacho, B., Prósper, F., Isidro, I. A., Alves, P. M., et al. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28378 · Cited by 46
“…cell transplantation regarding their low levels of immunogenicity, ability to cross the blood‐brain barrier while recapitulating the parental cells’ therapeutic effects and lower risk of tumorigenesis as they are not able to replicate (Banks et al., 2020; C. Y. Ng et al., 2022; Saleh et al., 2019).”
Background
Metadata
- Authors
- Banks, W. A., Sharma, P., Bullock, K. M., Hansen, K. M., Ludwig, N., & Whiteside, T. L.
- Affiliations
- University of Washington (US)
- University of Pittsburgh (US)
- Corresponding author
- Banks, William A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-06-21
- Volume
- 21
- Issue
- 12
- Pages
- 4407
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7352415
- OpenAlex
- W3036596408
- Cited by
- 561
- References
- 57
- Citations by year
- 2026: 99 · 2025: 102 · 2024: 132 · 2023: 90 · 2022: 81 · 2021: 54 · 2020: 2
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institutes of Health (1RO1 AG046619)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- extracellular vesicles, exosomes, blood-brain barrier, BBB crossing, brain pharmacokinetics, lipopolysaccharide, inflammation, mannose 6-phosphate receptor, CD46, integrins, ICAM-1, vesicular transporters
- MeSH terms
- Animals, Biological Transport, Blood-Brain Barrier, Cell Line, Humans, Inflammation, Male, Cell Line, Tumor, Mice, Exosomes, Transcytosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.